Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
EPS15
REST API REST API
Homo sapiens
EPS15 is differentially expressed in 329 experiments: 133 organism parts: liver, bone marrow, ... (131 more);, 203 disease states: normal, control, ... (201 more);, 91 cell types 387 cell lines 46 compound treatments and 85 other conditions.
Synonyms MLLT5, AF-1P
Orthologs Eps15 (Rattus norvegicus)   Eps15 (Mus musculus)   A5D7I1_BOVIN (Bos taurus)   EPS15 (Gallus gallus)   EPS15 (Danio rerio)   EDE1 (Saccharomyces cerevisiae)   Eps-15 (Drosophila melanogaster)   eps15 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, negative regulation of epidermal growth factor receptor signaling pathway, protein binding, cytoplasm, cell proliferation, epidermal growth factor receptor signaling pathway, clathrin coat assembly, clathrin-coated vesicle, SH3 domain binding, intracellular membrane-bounded organelle, coated pit, receptor activity, endosome, endocytic recycling, calcium ion binding, protein transport, vesicle organization, AP-2 adaptor complex, early endosome membrane
InterPro Term EPS15_homology, Ubiquitin-int_motif, EF_HAND_2, EF_hand_Ca-bd
UniProt Accession B1AUU8, A6NL94, P42566
Search EB-eye ENSG00000085832
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-7224, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (47 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
HCC38
2
E-MTAB-37, E-MTAB-62
SKBR3
2
E-MEXP-440, E-MTAB-62
SW480
2
E-GEOD-18005, E-MTAB-37
H820
1
E-MTAB-62
calu-1
1
E-MTAB-62
381 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (46 experiments)

Factor Value U/D Experiments
stromal cell
2
E-GEOD-3998, E-GEOD-10797
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
memory B cell
2
E-TABM-702, E-MEXP-2360
dendritic cell
1
E-GEOD-3982
mononuclear cell
1
E-GEOD-6053
CXCR4 positive
1
E-GEOD-15893
85 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (73 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MEXP-2034, E-MTAB-37, E-MEXP-1327
cervical carcinoma
3
E-MTAB-62, E-MEXP-1331, E-GEOD-5823
chronic myelogenous leukemia
3
E-GEOD-5550, E-MTAB-37, E-MTAB-62
glioblastoma
3
E-GEOD-4290, E-MEXP-567, E-GEOD-6014
adenocarcinoma
2
E-MTAB-62, E-MEXP-1331
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
197 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (28 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
2-(3,4,5-trimethoxy-phenylamino)-pyrrolo[2,3-d]pyrimidines
1
1
E-GEOD-6932
ponasterone A
1
E-GEOD-3113
5-aza-2'-deoxycytidine
1
E-MEXP-1269
valproic acid
1
E-GEOD-1615
4-hydroxytamoxifen
2
1
E-MEXP-2241
40 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-2666, E-GEOD-4667, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-MEXP-2280, E-TABM-147, ... (8 experiments)

Environmental stress
studied in E-GEOD-1518

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (9 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-7011, E-TABM-127, E-GEOD-20540, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (34 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (8 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (8 experiments)

pt
studied in E-GEOD-21653

Qpcr egfr dct
studied in E-GEOD-5851

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-18995

Sex
studied in E-GEOD-19743, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.275 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM